APMA Recommends Adoption of CDLEE as Part of NIH ODP 2024–2028 Strategic Planning | News | APMA
APMA Recommends Adoption of CDLEE as Part of NIH ODP 2024–2028 Strategic Planning

August 8, 2022

Doctors and staff standing with arms crossed

APMA submitted a recommendation that the NIH Office of Disease Prevention (ODP) support the development and dissemination of evidence on a Comprehensive Diabetic Lower Extremity Exam (CDLEE) service last Monday, in response to the NIH ODP’s Request for Information (RFI) on its Strategic Plan for Fiscal Years 20242028.

A national CDLEE service would help with prevention of diabetes-related lower extremity complications. It would also help with mental health, the efficiency of health-care delivery, and health-care spending. Further, improved health care that results from regular assessment and management of diabetes would support the administration’s commitment to advance health equity, given the well-documented higher prevalence of diabetes and resulting complications among minority and underserved communities. To read this letter in full, visit www.apma.org/commentletters.

If you have questions or concerns, contact the APMA Health Policy and Practice department at healthpolicy.hpp@apma.org.


Leave Your Thoughts

Please sign in to leave a comment

ADVERTISEMENT
Make a difference for your profession on Capitol Hill. Contribute to APMAPAC.